Pfizer’s next monthly obesity strategy, berobenatide, continued to show ongoing weight loss dynamics as patients transitioned from weekly dosing to monthly dosing in the VESPER-3 study. Data presented at the American Diabetes Association meeting suggested the rate of weight loss stayed similar after the switch and had not plateaued by 28 weeks. In the dataset described, patients lost up to 12.1% of body weight by 28 weeks among those who remained on treatment, though the report noted this trajectory still lags the pace seen at comparable time points in Eli Lilly’s Zepbound trial. The latest readout is aimed at validating monthly administration feasibility while maintaining clinically meaningful efficacy. Strategically, the update arrives as the oral and weekly incretin pipeline intensifies, with competitive pressure focused on durability, safety, and differentiation in weight-loss kinetics.